| Sildenafil improves walk distance in idiopathic pulmonary fibrosis. | |
| | |
MedLine Citation:
|
PMID: 17356110 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional status. Patients with IPF and documented pulmonary hypertension were followed up in an open-label study of sildenafil. The 6-min walk test distance (6MWD) was obtained before and after 3 months of sildenafil therapy. Fourteen patients were followed up in the study; 11 patients completed both 6-min walk tests. The mean improvement in walk distance was 49.0 m (90% confidence interval, 17.5 to 84.0 m). When all 14 patients were dichotomized into groups of "responders" (ie, >/= 20% improvement in 6MWD) or "nonresponders" (ie, < 20% change or unable to complete), 57% were classified as responders. Sildenafil is a promising and well-tolerated therapeutic agent for use in patients with IPF and pulmonary hypertension, and should be studied in a large, well-controlled trial. |
| | |
Authors:
|
Harold R Collard; Kevin J Anstrom; Marvin I Schwarz; David A Zisman |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Chest Volume: 131 ISSN: 0012-3692 ISO Abbreviation: Chest Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-03-14 Completed Date: 2007-05-02 Revised Date: 2008-11-20 |
Medline Journal Info:
|
Nlm Unique ID: 0231335 Medline TA: Chest Country: United States |
Other Details:
|
Languages: eng Pagination: 897-9 Citation Subset: AIM; IM |
Affiliation:
|
David Geffen School of Medicine at UCLA, 37-131 Center for Health Sciences, Los Angeles, CA 90095, USA. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00352482 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
3',5'-Cyclic-GMP Phosphodiesterases
/
antagonists & inhibitors* Aged Aged, 80 and over Cyclic Nucleotide Phosphodiesterases, Type 5 Exercise Test / drug effects* Female Follow-Up Studies Humans Hypertension, Pulmonary / drug therapy* Male Middle Aged Phosphodiesterase Inhibitors / therapeutic use* Piperazines / therapeutic use* Pulmonary Fibrosis / drug therapy* Pulmonary Wedge Pressure / drug effects Purines / therapeutic use Sulfones / therapeutic use* Vascular Resistance / drug effects Vasodilator Agents / therapeutic use* Walking* |
| Grant Support | |
ID/Acronym/Agency:
|
5P50HL67665/HL/NHLBI NIH HHS; 5U10HL080411/HL/NHLBI NIH HHS; U10 HL080411-02/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 139755-83-2/sildenafil; EC 3.1.4.35/3',5'-Cyclic-GMP Phosphodiesterases; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5; EC 3.1.4.35/PDE5A protein, human |
| Comments/Corrections | |
Comment In:
|
Chest. 2007 Mar;131(3):641-3
[PMID:
17356072
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Journal reporting of medical errors: the wisdom of Solomon, the bravery of Achilles, and the foolish...
Next Document: Video-assisted thorascopic removal of migratory acupuncture needle causing pneumothorax.